Pharmaceuticals company Zydus Lifesciences announced Q3FY25 results Revenue from operations at Rs 52,691 million, up 17% over Q3FY24. Research & Development (R&D;) investments for Q3FY25 stood at Rs 5,031 million (9.5% of revenues). EBITDA for Q3FY25 was Rs 13,876 million, up 26% YoY. EBITDA margin for Q3FY25 stood at 26.3%, which is an improvement of 180 bps on a YoY basis. Net Profit for Q3FY25 was Rs 10,235 million, up 30% YoY. Capex (organic) for Q3FY25 was Rs 2,907 million. Sharvil Patel, Managing Director, Zydus Lifesciences, said: We are pleased with the sustained growth momentum across our key businesses that has driven our Q3 performance. Our robust product portfolio execution in the US, market share gain in focused therapy segments and brands in India, and strategic leveraging of our global portfolio in International Markets position us well for future growth. We are on track to achieve our fiscal year 2025 goal of double-digit growth across our key businesses, coupled with improved profitability. Looking ahead, we are strategically building growth levers to ensure sustained success, with patient centricity and quality at the core of our operations. Result PDF